N@N

Market Maker Surveillance Report. BXG, SHP, XOMA, MOBI, MNKD, CAFI, Winning Stocks With Lowest Price Friction For Friday, Augu

^{Published on 2011-08-12 17:50:30 - WOPRAI}
 

August 12, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4359 companies with "abnormal" market making, 3443 companies with positive Friction Factors and 2848 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. BLUEGREEN CORP (NYSE:BXG), SHANGPHARMA CORP-ADR (NYSE:SHP), XOMA LTD (NASDAQ:XOMA), SKY-MOBI LTD-SP ADR (NASDAQ:MOBI), MANNKIND CORP (NASDAQ:MNKD), CAMCO FINANCIAL CORP (NASDAQ:CAFI). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     BXG        $0.530       23.14%       52,399          52.93%       31,905          32.23%       20,494          387     
     SHP        $1.950       25.32%       31,858          39.20%       28,318          34.84%       3,540           18      
     XOMA       $0.540       37.24%       1,526,621       55.56%       1,221,038       44.44%       305,583         5,659   
     MOBI       $1.160       21.89%       1,438,903       55.50%       1,103,830       42.57%       335,073         2,889   
     MNKD       $0.480       20.25%       3,294,208       50.69%       3,182,020       48.96%       112,188         2,337   
     CAFI       $0.560       44.80%       82,899          63.21%       45,542          34.73%       37,357          667     

For example, the chart above shows BXG with a dollar gain Friday of $0.53000 and a Friction Factor of 387 shares. That means that it only took 387 more shares of buying than selling to move BXG higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

BLUEGREEN CORP (NYSE:BXG) - Bluegreen Corporation provides places to live and play through its resorts and residential community businesses. It operates in two segments, Bluegreen Resorts and Bluegreen Communities. The Bluegreen Resorts segment markets, sells, and manages real estate-based vacation ownership interests (VOIs) in resorts located in the United States and Aruba. Its Bluegreen Vacation Club system permits the VOI owners to purchase a real estate timeshare interest, which provides them with an annual or biennial allotment of points that can be redeemed for occupancy rights at Bluegreen Vacation Club and club associate resorts. As of December 31, 2009, this segment managed approximately 222,600 VOI owners, including 168,500 members in the Bluegreen Vacation Club. It also provides resort management services to resort property owners associations. The Bluegreen Communities segment acquires, develops, and subdivides properties. It also markets residential land homesites to retail customers who seek to build a home on properties featuring a golf course and related amenities. It markets and sells homesites directly to retail consumers in communities primarily located in Texas, Georgia, and North Carolina. This segment also offers real estate consulting and other services to third parties. In addition, the company provides resort title services, resort amenity operations, non-cash sales incentives to buyers of VOIs, realty operations, and daily-fee golf course operations, as well as finance to individual purchasers of VOIs. Bluegreen Corporation was founded in 1966 and is headquartered in Boca Raton, Florida. As of November 16, 2009, Bluegreen Corp. operates as a subsidiary of Woodbridge Holdings, LLC.

SHANGPHARMA CORP-ADR (NYSE:SHP) - ShangPharma Corporation, through its subsidiaries, operates as a pharmaceutical and biotechnology research and development outsourcing company. The company provides a range of integrated services across the drug discovery and development process to international and Chinese pharmaceutical and biotechnology companies. Its services consist of discovery chemistry, discovery biology, and preclinical development, pharmaceutical development, and biologics services. The companys discovery chemistry services include medicinal chemistry, synthetic chemistry, library generation, and analytical chemistry; and discovery biology and preclinical development services comprise assay development and high throughput screening, pharmacology, reagent generation, DMPK, ADME profiling, metabolite identification, bioanalytical services, and non-GLP toxicology. Its pharmaceutical development services consist of preformulation and formulation, process research and development, analytical development, and research manufacturing; and biologics services, such as therapeutic antibody generation, antibody optimizing and engineering, and analytical services for large molecules. The company was founded in 2002 and is headquartered in Shanghai, the Peoples Republic of China.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

SKY-MOBI LTD-SP ADR (NASDAQ:MOBI) - Sky-mobi Limited operates the mobile application store in China. The company works with handset companies to pre-install its Maopao mobile application store on handsets and with content developers to provide users with applications and content titles. Users of its Maopao store can browse, download, and purchase a range of applications and content, such as single-player games, mobile music, and books. Its Maopao store enables mobile applications and content to be downloaded and run on various mobile handsets with different hardware and operating system configurations. The company also operates a mobile social network community in China, the Maopao Community, where it offers localized mobile social games, as well as applications and content with social network functions to its registered members. Sky-mobi Limited owns proprietary mobile application technology in the cloud computing, the MRP format, and SDK development environment. The company was formerly known as Profit Star Limited and changed its name to Sky-Mobi Limited in October 2010. The company was incorporated in 2007 and is based in Hangzhou, the Peoples Republic of China.

MANNKIND CORP (NASDAQ:MNKD) - MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate, AFREZZA, a rapid-acting insulin that has completed Phase III clinical trials for the treatment of diabetes in the United States, Europe, and Japan. The company is also preparing to initiate a Phase II study of MKC1106-MT in patients with advanced melanoma. Its products also include MKC253 (GLP-1), a Phase I clinical trials product for the treatment of type 2 diabetes; and MKC1106-PP, a Phase I clinical trials product for the treatment of diverse tumor types, metastatic diseases, and/or progressive, refractory disease. In addition, the company conducts preclinical studies of drug candidates, MKC204, which may have the potential to treat certain malignancies and inflammatory diseases; MKC180, an obesity compound; and MKC1106-NS, a cancer immunotherapy product. MannKind Corporation was founded in 1991 and is based in Valencia, California.

CAMCO FINANCIAL CORP (NASDAQ:CAFI) - Camco Financial Corporation, a financial services holding company, provides financial products and services in Ohio, Kentucky, and West Virginia. The company, through its subsidiary, Advantage Bank, offers a range of deposit products, including interest-bearing and non-interest bearing checking accounts, money market deposit accounts, regular savings accounts, health savings accounts, term certificate accounts, and retirement savings plans. It also provides commercial real estate and business loans; consumer loans; conventional fixed-rate and adjustable-rate mortgage loans for the construction, acquisition, and refinancing of single-family residential homes; and construction and permanent mortgage loans on condominiums, multi-family, and nonresidential properties. In addition, Camco Financial Corporation, through its other subsidiary, Camco Title Agency, Inc., offers title insurance services. As of May 17, 2010, it operated 28 offices in Ohio, Kentucky and West Virginia. The company was founded in 1970 and is based in Cambridge, Ohio.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net